BR112023003865A2 - Peptídeos dotados de atividade angiogênica - Google Patents
Peptídeos dotados de atividade angiogênicaInfo
- Publication number
- BR112023003865A2 BR112023003865A2 BR112023003865A BR112023003865A BR112023003865A2 BR 112023003865 A2 BR112023003865 A2 BR 112023003865A2 BR 112023003865 A BR112023003865 A BR 112023003865A BR 112023003865 A BR112023003865 A BR 112023003865A BR 112023003865 A2 BR112023003865 A2 BR 112023003865A2
- Authority
- BR
- Brazil
- Prior art keywords
- angiogenic activity
- peptides
- angiogenesis
- conditions
- peptides equipped
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 230000002491 angiogenic effect Effects 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 230000033115 angiogenesis Effects 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000002950 deficient Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
- C07K14/16—HIV-1 ; HIV-2
- C07K14/161—HIV-1 ; HIV-2 gag-pol, e.g. p55, p24/25, p17/18, p7, p6, p66/68, p51/52, p31/34, p32, p40
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
Abstract
peptídeos dotados de atividade angiogênica. a presente invenção refere-se a um peptídeo, ou a um derivado do mesmo, o qual tem um comprimento igual a ou menor do que 30 aminoácidos, e compreende qualquer uma das seq id nos 2, 3, 9, 10, 13, 14, 15, 16, 17, 18 ou um variante conservadora das mesmas, para ser usado como um medicamento, de preferência para ser usado no tratamento das condições associadas com/causadas por angiogênese deficiente ou por condições que se beneficia da angiogênese aumentada.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20194685.2A EP3964225A1 (en) | 2020-09-04 | 2020-09-04 | Peptides endowed with angiogenic activity |
| EP20199419 | 2020-09-30 | ||
| PCT/EP2021/074466 WO2022049280A1 (en) | 2020-09-04 | 2021-09-06 | Peptides endowed with angiogenic activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023003865A2 true BR112023003865A2 (pt) | 2024-03-12 |
Family
ID=78073882
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023003865A BR112023003865A2 (pt) | 2020-09-04 | 2021-09-06 | Peptídeos dotados de atividade angiogênica |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240091306A1 (pt) |
| EP (1) | EP4208186A1 (pt) |
| BR (1) | BR112023003865A2 (pt) |
| CA (1) | CA3192758A1 (pt) |
| IL (1) | IL300883A (pt) |
| WO (1) | WO2022049280A1 (pt) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006515161A (ja) * | 2002-08-09 | 2006-05-25 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | エリスロポエチンのｔ細胞エピトープ |
| EP2292642A1 (en) * | 2003-06-10 | 2011-03-09 | Opal Therapeutics Pty Ltd | Immunomodulating compositions, uses therefor and processes for their production |
| US9956265B2 (en) * | 2011-04-26 | 2018-05-01 | Ajou University Industry-Academic Cooperation Foundation | Composition for aiding surgical procedures for treating ischemic vascular diseases |
| CA2894166A1 (en) * | 2012-12-06 | 2014-06-12 | Pin Pharma, Inc. | Treatment of inflammation, autoimmune, and neurodegenerative disorders with immunosuppressive tat derivative polypeptides |
| US10752902B2 (en) * | 2014-09-23 | 2020-08-25 | Board Of Trustees Of Michigan State University | Compositions comprising fusion proteins useful for modulating an immune response |
-
2021
- 2021-09-06 BR BR112023003865A patent/BR112023003865A2/pt unknown
- 2021-09-06 IL IL300883A patent/IL300883A/en unknown
- 2021-09-06 EP EP21786091.5A patent/EP4208186A1/en active Pending
- 2021-09-06 CA CA3192758A patent/CA3192758A1/en active Pending
- 2021-09-06 US US18/024,624 patent/US20240091306A1/en active Pending
- 2021-09-06 WO PCT/EP2021/074466 patent/WO2022049280A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| CA3192758A1 (en) | 2022-03-10 |
| EP4208186A1 (en) | 2023-07-12 |
| WO2022049280A1 (en) | 2022-03-10 |
| IL300883A (en) | 2023-04-01 |
| US20240091306A1 (en) | 2024-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP21070640A (es) | Composición farmacéutica para inyección subcutánea que comprende una variante de hialuronidasa humana ph20 y un medicamento | |
| PE20240015A1 (es) | Proteinas de fusion gdf15 y usos de estas | |
| BRPI1010120A2 (pt) | composição de surfactante reconstituído melhorada contendo análogos de proteína b do surfactante (sp-b) e proteína c do surfactante ( sp-c) | |
| NZ595063A (en) | Polypeptides from neisseria meningitidis | |
| PE20121393A1 (es) | Analogo peptidico de oxintomodulina | |
| HRP20110242T1 (hr) | Formulacija s fuzijskim proteinom glp-1-fc | |
| CR20130234A (es) | Métodos de tratamiento de trastornos asociados con el fgf21 | |
| ATE544461T1 (de) | Rekonstituierte tenside mit verbesserten eigenschaften | |
| NZ597306A (en) | Mesenchymal stem cell differentiation | |
| JP2014519526A5 (pt) | ||
| MX2021014497A (es) | Peptidos. | |
| BR112023003865A2 (pt) | Peptídeos dotados de atividade angiogênica | |
| CR20220206A (es) | Agonistas del receptor npy2 | |
| PE20221663A1 (es) | Composicion para prevenir o tratar enfermedades pulmonares que comprende proteina 1 de union de hialuronano y proteoglucano | |
| CL2023003169A1 (es) | Alfa-1-antitripsina (aat) en el tratamiento y/o prevención de trastornos neurológicos | |
| CR20230074A (es) | Agonistas del receptor npy2 solubles | |
| Shin et al. | Antinociceptive effects of A1 and A2 type botulinum toxins on carrageenan-induced hyperalgesia in rat | |
| EA202090802A1 (ru) | Пептидная композиция для лечения повреждений, связанных с возбуждающей нейротоксичностью | |
| MX2018012716A (es) | Peptidos bioactivos pegilados y usos de los mismos. | |
| BR112021020926A2 (pt) | Um novo tipo de composição de enzima | |
| PE20211772A1 (es) | Inmunoterapia con peptidos restringidos a b 08 y una combinacion de peptidos contra el cancer y metodos relacionados | |
| ATE552271T1 (de) | Antitumorarzneimittel, medikament, zusammensetzung und anwendung davon | |
| BR112013029596B8 (pt) | Composição imunogênica | |
| BR112022005327A2 (pt) | Composição farmacêutica compreendendo conjugado de peptídeo trombolítico-tetraidroisoquinolina | |
| MX2024002941A (es) | Peptidos con actividad antiangiogenica. |